Healthcare / BiotechnologyBSE
$1115.90
+10.65 (+0.96%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 23% · confianza 25%
FCF escenarios
weak_data · normalized FCF $264.4M · quality 80.7/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
55/100
C
Piotroski
7/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$9.6B
P/E
16.0x
↓EV/EBITDA
14.5x
↑ROE
17.8%
↑Gross Margin
73.4%
↑Debt/Equity
0.00
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
+6.2%
FCF CAGR
+6.6%
FCF margin
44.0%
FCF / Net income
0.89x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $964.7M · net income $476.5M · FCF $424.5M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $964.7M | $964.7M | $741.2M | $618.4M | $806.5M |
| Net Income | $476.5M | $476.5M | $327.3M | $259.4M | $322.0M |
| EBITDA | $651.9M | $651.9M | $455.1M | $363.7M | $440.0M |
| EPS | 55.66 | 55.66 | 37.46 | 30.27 | 43.40 |
| Gross Margin | 73.4% | 73.4% | 70.5% | 71.0% | 60.8% |
| Operating Margin | 50.8% | 50.8% | 43.1% | 46.3% | 45.2% |
| Net Margin | 49.4% | 49.4% | 44.2% | 41.9% | 39.9% |
| Balance Sheet | |||||
| Debt/Equity | 0.00 | 0.00 | 0.00 | 0.01 | 0.02 |
| Current Ratio | 5.27 | 5.27 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $424.5M | $424.5M | $264.4M | $182.6M | $350.6M |
| Returns | |||||
| ROE | 17.8% | 17.8% | 14.7% | 13.4% | 21.0% |
| Valuation | |||||
| P/E | 15.95 | 15.95 | 19.77 | 14.41 | 8.74 |
| EV/EBITDA | 14.47 | 14.47 | 13.95 | 10.18 | 5.89 |
| P/B | 3.56 | 3.56 | 2.90 | 1.93 | 1.86 |
| Growth & Yield | |||||
| Revenue Growth | 30.1% | 30.1% | 19.9% | -23.3% | — |
| EPS Growth | 48.6% | 48.6% | 23.8% | -30.3% | — |
| Dividend Yield | 0.4% | 0.4% | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
3Y implied EPS CAGR
21.2%
EPS terminal req.
$99.02
Spread vs growth
27.4%
5Y implied EPS CAGR
16.6%
EPS terminal req.
$119.81
Spread vs growth
32.0%
10Y implied EPS CAGR
13.2%
EPS terminal req.
$192.96
Spread vs growth
35.3%
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-40.6%
Start / end P/E
50.4x → 20.0x
EPS bridge
37.46 → 55.66
Residual
-29.3%
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.